TORONTO and CHICAGO and MONTREAL (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today provided a business update and announced its financial and operating results for the three- and nine-month periods ended December 31, …
Trending at Lumira Ventures
Endotronix Enrolls First Patients in PROACTIVE-HF Pivotal Trial
LISLE, Ill. /PRNewswire/ — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal trial. The trial is a pre-market …
Antios Therapeutics Initiates First-in-Human Phase 1 Study of ATI-2173
ATLANTA /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase 1 clinical trial for ATI-2173, a novel liver-targeted, orally-administered, …
Frontiers in Oncology Publishes New Meta-Analysis on the Diagnostic Value of Micro-Ultrasound
Published in December 2019, Frontiers in Oncology, one of the world’s top peer-reviewed oncology journals in terms of influence and quality, published a new meta-analysis on the diagnostic value of micro-ultrasound in prostate cancer. Key findings show that micro-ultrasound is …
Satsuma Pharmaceuticals Publishes Phase 1 Trial Results
SOUTH SAN FRANCISCO, California (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing pharmacokinetics (PK), tolerability, and safety with its lead product candidate, STS101 (DHE (or dihydroergotamine) nasal powder …
Zymeworks Announces Closing of US$320.8M Public Offering
VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (“Zymeworks” or the “Company”), announced today the closing of its previously announced underwritten public offering (the “Offering”). The Offering consisted of 5,824,729common shares, including the …
Bardy Diagnostics™ Commercially Launches its 14-Day CAM™ Patch
SEATTLE /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today the commercial launch of the 14-Day version of the Carnation Ambulatory Monitor (“CAM™”), the industry’s only P-wave centric™ ambulatory cardiac …
Histotripsy Tumor Ablation Research is Published in the Journal for ImmunoTherapy of Cancer
On January 15, 2020, HistoSonics’ research on non-thermal histotripsy tumor ablation was published in the Journal for ImmunoTherapy of Cancer (JITC), the premier cancer immunotherapy journal at BMC and the official journal of the Society for Immunotherapy of Cancer (SITC). …
Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia—(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME) (“Zymeworks” or the “Company”), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Canadian Supplement”) to its Canadian short form base shelf prospectus dated November 18, …
HistoSonics Leads The Observer’s 2020 List of Innovative Healthcare Companies
PLYMOUTH, Minn. /PRNewswire/ — HistoSonics, developer of a novel non-invasive sonic beam therapy platform, was named by The Observer as one of the nation’s most influential healthcare companies during the 38th J.P. Morgan Healthcare Investment Conference in San Francisco, CA. The …
G1 Therapeutics & Quantum Leap Healthcare Collaborate in Breast Cancer Research Study
SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated …
Corvia Medical’s Global Clinical Trial Begins Randomization in Japanese Patients
TEWKSBURY, Mass. /PRNewswire/ — Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization from the Pharmaceutical …
Opsens Receives FDA Approval for Optowire III
QUEBEC CITY /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today announced 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its OptoWire III, a coronary pressure guidewire for physiological measurements such as Fractional Flow Reserve …
Bardy Diagnostics™ Appoints Ed Vertatschitsch as COO
SEATTLE / PRNewswire / — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor (“CAM™”), the only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, announced today the …
Zymeworks Inks Collaboration Agreement with Pfizer in Breast Cancer Study
VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific …